MSC growth and phenotype
| . | Follicular lymphoma patients (n = 10) . | Healthy donors (n = 6) . | P . |
|---|---|---|---|
| Sex ratio, M/F | 8/2 | 4/2 | |
| Age (y)* | 58.5 (42-76) | 54.0 (30-78) | |
| BM CFU-F* | 52.5 (10.5-625) | 161.7 (23.5-506) | .3132 |
| PD* | |||
| PD at P0 | 13.3 (11-15.1) | 12.7 (10.2-14.6) | .8749 |
| PD at P1 | 5.1 (3-5.8) | 5.4 (4.3-6.1) | .3831 |
| Total PD | 18.1 (14.1-20.9) | 18 (16.3-19.5) | .8749 |
| Karyotype | 46, XX [30] (2) | 46, XX [30] (2) | |
| 46, XY [30] (8) | 46, XY [30] (4) | ||
| Phenotype at the end of P1† | |||
| CD45 | 0.2 (0-0.5) | 0.2 (0-0.2) | |
| CD19 | 0.1 (0-0.3) | 0 (0-0.2) | |
| CD105 | 99.9 (99.1-100) | 99.6 (99.3-100) | |
| CD90 | 99.8 (99.5-100) | 99.9 (99.8-100) | |
| CD73 | 99.8 (99.5-100) | 99.9 (99.5-100) |
| . | Follicular lymphoma patients (n = 10) . | Healthy donors (n = 6) . | P . |
|---|---|---|---|
| Sex ratio, M/F | 8/2 | 4/2 | |
| Age (y)* | 58.5 (42-76) | 54.0 (30-78) | |
| BM CFU-F* | 52.5 (10.5-625) | 161.7 (23.5-506) | .3132 |
| PD* | |||
| PD at P0 | 13.3 (11-15.1) | 12.7 (10.2-14.6) | .8749 |
| PD at P1 | 5.1 (3-5.8) | 5.4 (4.3-6.1) | .3831 |
| Total PD | 18.1 (14.1-20.9) | 18 (16.3-19.5) | .8749 |
| Karyotype | 46, XX [30] (2) | 46, XX [30] (2) | |
| 46, XY [30] (8) | 46, XY [30] (4) | ||
| Phenotype at the end of P1† | |||
| CD45 | 0.2 (0-0.5) | 0.2 (0-0.2) | |
| CD19 | 0.1 (0-0.3) | 0 (0-0.2) | |
| CD105 | 99.9 (99.1-100) | 99.6 (99.3-100) | |
| CD90 | 99.8 (99.5-100) | 99.9 (99.8-100) | |
| CD73 | 99.8 (99.5-100) | 99.9 (99.5-100) |
Standard karyotype was performed at the end of P1 by analyzing 30 RHG-banded metaphases. Total PD = cumulative number of PD (PD at P0 + PD at P1). BM CFU-F indicates number of CFU-F/106 BM mononuclear cells; MSC, mesenchymal stromal cells; and PD, population doubling.
Data are expressed as median (range).
Data are expressed as median percentage (range).